Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. / McLean, R T; Wilson, Philip; St Clair, D; Mustard, C J; Wei, J.

In: Translational Psychiatry, Vol. 7, No. 5, e1121, 2017.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

McLean, RT, Wilson, P, St Clair, D, Mustard, CJ & Wei, J 2017, 'Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia', Translational Psychiatry, vol. 7, no. 5, e1121. https://doi.org/10.1038/tp.2017.89

APA

McLean, R. T., Wilson, P., St Clair, D., Mustard, C. J., & Wei, J. (2017). Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. Translational Psychiatry, 7(5), [e1121]. https://doi.org/10.1038/tp.2017.89

Vancouver

McLean RT, Wilson P, St Clair D, Mustard CJ, Wei J. Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. Translational Psychiatry. 2017;7(5). e1121. https://doi.org/10.1038/tp.2017.89

Author

McLean, R T ; Wilson, Philip ; St Clair, D ; Mustard, C J ; Wei, J. / Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. In: Translational Psychiatry. 2017 ; Vol. 7, No. 5.

Bibtex

@article{b308db13d7934031be73c3dd3a000b9c,
title = "Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia",
abstract = "Gluten consumption has previously been implicated in the development of schizophrenia while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma immunoglobulin G (IgG) and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined the plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had the increased levels of plasma IgG against the γ-gliadin-derived fragment, namely AAQ6C, but decreased levels of plasma IgG against the α- and γ3-gliadin-derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of eight gliadin-derived antigens tested, four showed a sensitivity of >20{\%} against the specificity of ⩾95{\%} for detection of their corresponding antibodies in plasma. These four tests may thus have a potential to serve as biomarkers for the identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.",
keywords = "Adult, Antibody Formation/drug effects, Antigens, Autoantibodies/drug effects, Biomarkers/blood, Enzyme-Linked Immunosorbent Assay/methods, Female, Gliadin/immunology, Glutens/adverse effects, Humans, Immunoglobulin A/blood, Immunoglobulin G/blood, Male, Middle Aged, Peptides/immunology, Schizophrenia/blood",
author = "McLean, {R T} and Philip Wilson and {St Clair}, D and Mustard, {C J} and J Wei",
year = "2017",
doi = "10.1038/tp.2017.89",
language = "English",
volume = "7",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "nature publishing group",
number = "5",

}

RIS

TY - JOUR

T1 - Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia

AU - McLean, R T

AU - Wilson, Philip

AU - St Clair, D

AU - Mustard, C J

AU - Wei, J

PY - 2017

Y1 - 2017

N2 - Gluten consumption has previously been implicated in the development of schizophrenia while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma immunoglobulin G (IgG) and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined the plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had the increased levels of plasma IgG against the γ-gliadin-derived fragment, namely AAQ6C, but decreased levels of plasma IgG against the α- and γ3-gliadin-derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of eight gliadin-derived antigens tested, four showed a sensitivity of >20% against the specificity of ⩾95% for detection of their corresponding antibodies in plasma. These four tests may thus have a potential to serve as biomarkers for the identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.

AB - Gluten consumption has previously been implicated in the development of schizophrenia while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma immunoglobulin G (IgG) and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined the plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had the increased levels of plasma IgG against the γ-gliadin-derived fragment, namely AAQ6C, but decreased levels of plasma IgG against the α- and γ3-gliadin-derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of eight gliadin-derived antigens tested, four showed a sensitivity of >20% against the specificity of ⩾95% for detection of their corresponding antibodies in plasma. These four tests may thus have a potential to serve as biomarkers for the identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.

KW - Adult

KW - Antibody Formation/drug effects

KW - Antigens

KW - Autoantibodies/drug effects

KW - Biomarkers/blood

KW - Enzyme-Linked Immunosorbent Assay/methods

KW - Female

KW - Gliadin/immunology

KW - Glutens/adverse effects

KW - Humans

KW - Immunoglobulin A/blood

KW - Immunoglobulin G/blood

KW - Male

KW - Middle Aged

KW - Peptides/immunology

KW - Schizophrenia/blood

U2 - 10.1038/tp.2017.89

DO - 10.1038/tp.2017.89

M3 - Journal article

C2 - 28485731

VL - 7

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 5

M1 - e1121

ER -

ID: 217945347